Repligen RGEN 深 沪
已收盘 12-12 16:00:00 美东时间
157.39
-4.270
-2.64%
华盛通- 最 高162.0595
- 今 开161.26
- 成交量 66.06万股
- 最 低 156.31
- 昨 收 161.66
- 总市值 88.54亿
- 52周最高 182.52
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 102.965
- 委 比 -99.28%
- 总股本 5625.76万
- 历史最高 327.32
- 量 比 1.16
- 振 幅 3.56%
- 历史最低 2.90
- 每 手 1
- 风险率 16.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Repligen Corporation to Present at Evercore Healthcare Conference
Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, from December 2-4. Jason Garland, CFO, will join an analyst-led discussion on December 3 at 1:20 p.m. ET. A live webcast will be available via Repligen’s Investor Relations website at www.repligen.com, with a limited replay option post-event. Repligen, a global life sciences company, specializes in bioprocessing technologies for biolog...
11-26 12:30
P/E Ratio Insights for Repligen
In the current market session, Repligen Inc. (NASDAQ:RGEN) share price is at $1...
11-22 02:00
Repligen Corporation to Present at Upcoming November Conferences
Repligen Corporation announced it will attend five upcoming investor conferences in November 2025, including the UBS Global Healthcare Conference, Stifel Healthcare Conference, Wolfe Research Healthcare Conference, Jefferies Global Healthcare Conference, and Stephens Annual Investment Conference. executives Jason Garland and Olivier Loeillot will participate in analyst discussions and investor meetings across these events. Live webcasts will be a...
11-04 12:30
Earnings Preview For Bruker
Bruker (NASDAQ:BRKR) is gearing up to announce its quarterly earnings on Monday...
11-01 00:02
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Barclays Maintains Overweight on Repligen, Raises Price Target to $175
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $160 to $175.
10-29 21:32
Repligen Narrows FY2025 Adj EPS Guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 Est; Raises FY2025 Sales Guidance from $715.000M-$735.000M to $729.000M-$737.000M vs $726.458M Est
Repligen (NASDAQ:RGEN) narrows FY2025 Adj EPS guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 analyst estimate. Raises FY2025 sales outlook from $715.000 million-$735.000 million to $729.000 million-$737.000 million vs
10-28 19:31
Repligen Q3 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $188.805M Beat $181.338M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.42 by 10.05 percent. This is a 6.98 percent increase over earnings of $0.43 per share from the same
10-28 19:30
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
优然牧业赛科星再添全球最先进新款性控分离机，总装机量达15台，领跑行业！
科技赋能 近期，优然牧业赛科星迎来了重大利好消息，公司成功从美国引进了全球最先进的新款性控分离机。这是国内落地的第一台也是公司拥有的第15台性控分离机，进一步巩...
10-10 17:10
